欢迎访问《现代生物医学进展》编辑部！

目的：研究瑞格列奈联合二甲双胍对西宁地区2 型糖尿病患者纤维蛋白溶酶原激活抑制因子-1 (PAI-1)水平的影响。方法：选择2012 年2 月～2015 年9 月在我院进行诊治的2 型糖尿病患者98 例，随机分为三组，分别用瑞格列奈、二甲双胍单独治疗和两药联合治疗。在治疗前后分别检测空腹血糖、糖化血红蛋白和PAI-1水平。结果：联合用药组的治疗总有效率为94.12%，明显高于瑞格列奈组(71.87%)和二甲双胍组(75.00%) (P<0.05)；瑞格列奈组和二甲双胍组治疗6 周后，空腹血糖、糖化血红蛋白和PAI-1 水平均明显降低(P<0.05)，但两单独用药组间相比无显著性差异；联合治疗组上述指标均较单独用药明显降低(P<0.05)。联合治疗期间低血糖和胃肠不适的发生率较单独用药无明显升高。结论：瑞格列奈和二甲双胍可较单药治疗进一步降低2 型糖尿病患者的PAI-1 水平，这可能有助于改善患者的血液凝固程度，减少血管相关并发症，且无明显不良反应，值得临床应用推广。

英文摘要:

Objective:To investigate the clinical effect of repaglinide combined with metformin on the PAI-1 levels of type 2 diabetic patients in Xining area.Methods:98 cases of patients with type 2 diabetes admitted in our hospital from January 2012 to September 2015 were selected and divided into three groups, which were treated with repaglinide, metformin, and both drugs. The fasting blood glucose, glycosylated hemoglobin and PAI-1 levels were detected.Results:The effective rate of combination group was 94.12%, which was significantly higher than the repaglinide group(71.87%) and metformin group (75.00%) (P<0.05). After treatment, the FBG, HBA1c and PAI-1 levels of three groups were significantly decreased (P<0.05), which were significantly lower in the combination group than those of repaglinide group and metformin group (P<0.05) No obvious difference was found in the incidence of hypoglycemia and gastrointestinal among three groups.Conclusion:Compared with single drug treatment, repaglinide combined with metformin could more effectively reduce the PAI-1 levels of patients with type 2 diabetes, which might contribute to the improvement of blood coagulation, decrease of vascular complications, and had no obvious adverse reactions.

View Full Text View/Add Comment Download reader